Flag of the European Union EU Clinical Trials Register Help

Clinical trials for hepatitis hu

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43861   clinical trials with a EudraCT protocol, of which   7284   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    147 result(s) found for: hepatitis hu. Displaying page 1 of 8.
    1  2  3  4  5  6  7  8  Next»
    EudraCT Number: 2014-004111-37 Sponsor Protocol Number: BHC-ABT-001 Start Date*: 2014-10-22
    Sponsor Name:BUDAI HEPATOLÓGIAI CENTRUM
    Full Title: Individual Patient Access to AbbVie ABT-450/rítonavir/ABT-267 and ABT 333 Coadministered witb Ribavirín (RBV) in Patient with Genotype 1 Hepatitis C Vírus Infection witb Cirrhosis
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002069-77 Sponsor Protocol Number: RG101-05 Start Date*: 2016-12-01
    Sponsor Name:Regulus Therapeutics Inc.
    Full Title: An Observational Long-Term Safety and Efficacy Follow-Up Study of Subjects Who Have Previously Received RG-101
    Medical condition: Hepatitis C Patients
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    19.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    19.0 10021881 - Infections and infestations 10019761 Hepatitis cytomegalovirus LLT
    19.0 100000004848 10057394 Hepatitis C positive LLT
    19.0 10021881 - Infections and infestations 10019760 Hepatitis CMV LLT
    19.0 10021881 - Infections and infestations 10047457 Viral hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GR (Completed) HU (Completed)
    Trial results: (No results available)
    EudraCT Number: 2010-021473-36 Sponsor Protocol Number: KB050 Start Date*: 2011-11-22
    Sponsor Name:KEDRION
    Full Title: Efficacy and Safety evaluation of Kedrion Human Hepatitis B Immunoglobulin for intramuscular use in the prevention of hepatitis B in the newborns of Hepatitis B Virus carrier-mothers: multi-centr...
    Medical condition: Newborns of hepatitis B virus carrier mothers
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019619 Hep B LLT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2010-018361-33 Sponsor Protocol Number: HCV689-201 Start Date*: 2010-09-10
    Sponsor Name:Arrow Therapeutics Ltd. (a member of the AstraZeneca group of companies)
    Full Title: A Randomised, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Determine the Efficacy, Safety and Tolerability of AZD7295 in Combination with Pegylated Interferon alpha-2a and Ribavirin in P...
    Medical condition: Chronic hepatitis C virus (genotype 1b) infection
    Disease: Version SOC Term Classification Code Term Level
    12.1 10008912 Chronic hepatitis C LLT
    12.1 10019744 Hepatitis C LLT
    12.1 10019751 Hepatitis C virus LLT
    12.1 10047457 Viral hepatitis C LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: SK (Completed) HU (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001180-53 Sponsor Protocol Number: TMC435HPC3001 Start Date*: 2012-01-06
    Sponsor Name:Janssen R&D Ireland
    Full Title: A Phase III, randomized, double-blind trial to evaluate the efficacy, safety and tolerability of TMC435 vs. telaprevir, both in combination with PegIFNα-2a and ribavirin, in chronic hepatitis C gen...
    Medical condition: Hepatitis C Virus (HCV) genotype-1 infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) GR (Completed) BE (Completed) ES (Completed) DE (Completed) SE (Completed) HU (Completed) AT (Completed) DK (Completed) PL (Completed) CZ (Completed) NO (Completed) GB (Completed) IT (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2014-003413-28 Sponsor Protocol Number: TMC435HPC2019 Start Date*: 2014-12-05
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2, Open-label Study to Investigate the Efficacy and Safety of the Combination of Simeprevir and Daclatasvir in Chronic Hepatitis C Genotype 1b-Infected Subjects With Advanced Liver Disease
    Medical condition: Hepatitis C Virus (HCV) genotype-1b Infection
    Disease: Version SOC Term Classification Code Term Level
    17.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) DE (Completed) BE (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-000946-39 Sponsor Protocol Number: GS-US-248-0123 Start Date*: 2011-11-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Long Term Follow-up Registry Study of Subjects Who Did Not Achieve Sustained Virologic Response in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection
    Medical condition: Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) FR (Completed) CZ (Completed) HU (Prematurely Ended) PL (Completed) IT (Completed) AT (Completed) SE (Completed) ES (Completed) EE (Completed) NL (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2011-000945-19 Sponsor Protocol Number: GS-US-248-0122 Start Date*: 2011-11-21
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Long Term Follow-up Registry for Subjects Who Achieve a Sustained Virologic Response to Treatment in Gilead Sponsored Trials in Subjects with Chronic Hepatitis C Infection
    Medical condition: Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    20.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) GB (Prematurely Ended) FR (Prematurely Ended) CZ (Prematurely Ended) HU (Prematurely Ended) PL (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) SE (Completed) ES (Prematurely Ended) EE (Prematurely Ended) NL (Prematurely Ended) BE (Completed)
    Trial results: View results
    EudraCT Number: 2010-023669-23 Sponsor Protocol Number: VX-950HEP3002 Start Date*: 2011-04-06
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Multicenter, Open-Label, Early Access Program of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Genotype 1 Chronic Hepatitis C Subjects With Severe Fibrosis and Compensated Cirr...
    Medical condition: Chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004848 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) IT (Completed) CZ (Completed) GR (Completed) ES (Completed) HU (Completed) SK (Completed)
    Trial results: View results
    EudraCT Number: 2011-000456-42 Sponsor Protocol Number: GS-US-256-0148 Start Date*: 2011-10-04
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating Response Guided Therapy with GS 5885 Alone or in Combination with GS-9451 with Peginterferon Alfa 2a and Ribavirin in Treat...
    Medical condition: Genotype 1 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    13.1 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    13.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) CZ (Completed) HU (Completed) BG (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-003593-85 Sponsor Protocol Number: VX-950HPC3005 Start Date*: 2012-04-26
    Sponsor Name:Janssen-Cilag International NV
    Full Title: Multicenter, Open-Label Study of Telaprevir in Combination With Peginterferon Alfa and Ribavirin in Human Immunodeficiency Virus/Genotype 1 Chronic Hepatitis C Coinfected Subjects With Severe Fibro...
    Medical condition: Chronic hepatitis C infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10022891 - Investigations 10019752 Hepatitis C virus (HCV) LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) AT (Completed) DE (Completed) GB (Completed) PT (Completed) HU (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2010-020033-14 Sponsor Protocol Number: CDEB025A2210 Start Date*: 2010-09-03
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicentre, randomized, double-blind, placebocontrolled, parallel-group phase II study on efficacy and safety of DEB025 combined with peg-IFN alfa-2a and ribavirin in chronic hepatitis C genotyp...
    Medical condition: Chronic Hepatitis C Genotype 1 patients
    Disease: Version SOC Term Classification Code Term Level
    15.0 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) HU (Completed) DE (Completed) FR (Completed) ES (Completed) BE (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2014-004939-39 Sponsor Protocol Number: GS-EU-174-1403 Start Date*: 2015-05-26
    Sponsor Name:Gilead Sciences International Ltd.
    Full Title: Pharmacoepidemiology study to define the long-term safety profile of tenofovir disoproxil fumarate (Tenofovir DF, Viread®) and describe the management of Tenofovir DF-associated renal and bone toxi...
    Medical condition: Chronic Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    18.0 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adolescents, Under 18 Gender: Male, Female
    Trial protocol: BE (Completed) GB (Prematurely Ended) ES (Prematurely Ended) BG (Prematurely Ended) GR (Completed) FR (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003687-52 Sponsor Protocol Number: M13-961 Start Date*: 2013-03-01
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Randomized, Double-Blind, Controlled Study to Evaluate the Efficacy and Safety of the Combination of ABT-450/Ritonavir/ABT-267 (ABT 450/r/ABT-267) and ABT-333 With and Without Ribavirin (RBV) in ...
    Medical condition: Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: PT (Completed) BE (Completed) HU (Completed) AT (Completed) IT (Completed) ES (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-003354-89 Sponsor Protocol Number: 5172-035 Start Date*: 2013-03-28
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc. USA
    Full Title: A Phase II Randomized Clinical Trial to Study the Efficacy and Safety of the combination regimen of MK-5172 and MK-8742 +/-Ribavirin (RBV) in Subjects with Chronic Hepatitis C Virus Infection
    Medical condition: Hepatitis C Virus Genotype 1 (HCV GT 1)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) DK (Completed) HU (Completed) ES (Completed) SE (Completed) FR (Completed)
    Trial results: View results
    EudraCT Number: 2011-005287-21 Sponsor Protocol Number: AI444-046 Start Date*: 2012-02-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Long-Term Follow-up Study of Subjects Who Participated in a Clinical Trial in Which Asunaprevir (BMS-650032) and/or Daclatasvir (BMS-790052) Was Administered for the Treatment of Chronic Hepatiti...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) IE (Completed) SE (Completed) IT (Completed) GB (Completed) DK (Completed) ES (Completed)
    Trial results: View results
    EudraCT Number: 2011-004810-41 Sponsor Protocol Number: MV28073 Start Date*: 2012-04-18
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: An international, multicenter, open-label study evaluating sustained virological response and safety with Boceprevir in triple combination therapy with Peginterferon alfa-2a (40KD) and Ribavirin in...
    Medical condition: Genotype 1 CHC virus infection
    Disease: Version SOC Term Classification Code Term Level
    16.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: AT (Completed) HU (Completed) ES (Completed) PL (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-006131-38 Sponsor Protocol Number: CDEB025A2312 Start Date*: 2012-05-18
    Sponsor Name:Novartis Farmaceutica, S.A.
    Full Title: A multi-centre 3-year follow-up study to assess the durability of sustained virologic response in alisporivir treated chronic hepatitis C patients
    Medical condition: Chronic hepatitis C in patients who achieved sustained virologic response (SVR24) on alisporivir in a Novartis-sponsored chronic Hepatitis C study.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) GB (Completed) PL (Completed) IT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2011-005762-38 Sponsor Protocol Number: M13-393 Start Date*: 2012-05-31
    Sponsor Name:Abbott GmbH & Co. KG
    Full Title: A Randomized, Open-Label Study to Evaluate the Safety and Efficacy of Coadministration of ABT-450 with Ritonavir (ABT-450/r) and ABT-267 in Adults with Chronic Hepatitis C Virus Infection (PEARL-I)
    Medical condition: Chronic Hepatitis C Infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10019805 - Hepatobiliary disorders 10008909 Chronic hepatitis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) HU (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2012-003508-11 Sponsor Protocol Number: AI452-033 Start Date*: 2013-08-09
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Double-Blinded, Randomized Control Study Evaluating the Efficacy and Safety of Peginterferon Lambda-1a Compared to Peginterferon alfa-2a, Each in Combination with Ribavirin, in the Treatment of N...
    Medical condition: Chronic Hepatitis C Virus Infection (Genotype 1)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: CZ (Prematurely Ended) PL (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Thu Apr 25 18:49:12 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA